Overview

Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients

Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The present study aims to investigate whether the dosage of the GnRH agonist used for triggering final oocyte maturation affects the maturity of the oocytes retrieved in high risk for OHSS patients undergoing ovarian stimulation for IVF using GnRH antagonists and recombinant FSH.
Phase:
Phase 2
Details
Lead Sponsor:
Aristotle University Of Thessaloniki
Collaborator:
Eugonia IVF Unit, Athens, Greece
Treatments:
Deslorelin
Triptorelin Pamoate